Source comparison
MK-677 DSIP Protocol: Peptide Comparison
This table compares the primary peptides in the mk-677 dsip protocol sleep + gh research stack and their distinct mechanisms. MK-677 (Ibutamoren) Ghrelin receptor agonist. Stimulates GHRH release from hypothalamus Pulsatile GH secretion increase (60–127% above
This comparison does not assign a generated winner or score.
- This table compares the primary peptides in the mk-677 dsip protocol sleep + gh research stack and their distinct mechanisms.
- MK-677 (Ibutamoren)
- Ghrelin receptor agonist. Stimulates GHRH release from hypothalamus
- Pulsatile GH secretion increase (60–127% above baseline)
- 15–25mg once daily
- Oral (capsule or powder)
- 4–6 hours
- Gold standard for non-suppressive GH elevation; appetite increase is dose-dependent and must be controlled in metabolic studies
- DSIP (Delta Sleep-Inducing Peptide)
- Serotonergic/dopaminergic modulation in sleep centres; cortisol suppression
- Delta-wave amplitude increase (40–60%); evening cortisol reduction (20–35%)
- 100–300mcg before sleep
- Subcutaneous or intranasal
- 15–30 minutes (rapid clearance)
- Best-in-class for sleep architecture without REM suppression; effects are cumulative over 7–14 days rather than acute
- CJC-1295 (comparator)
- GHRH analogue. Direct pituitary GH release
- Sustained GH elevation (non-pulsatile)
- 1–2mg per week
- Subcutaneous injection
- 6–8 days (with DAC modification)
- Effective for sustained GH but lacks pulsatility; often combined with GHRP-2 or GHRP-6 to restore natural secretion patterns
- GHRP-2 (comparator)
- Growth hormone secretagogue receptor agonist
- GH pulse induction (less pronounced than MK-677)
- 100–300mcg 2–3x daily
- 20–30 minutes
- Requires multiple daily dosing; more prone to desensitisation than MK-677; often stacked with CJC-1295